GERNGeron CorporationRunning, no new patients
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Myelofibrosis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 327 (final count)
- Started
- Apr 12, 2021
- Main results expected
- Jun 30, 2028
- Fully finished
- Jun 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall survival (OS)
Measured over: Baseline (Day 1) until End of Study (EOS) (approximately 3 years )]
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04576156 · record last updated 2026-07-08 · checked 2026-11-09 15:47 UTC